Systemic lupus erythematosus is an autoimmune disease that seriously endangers human health. On December 6th, it was learned from the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) that the research team of Professor Zhao Dongbao and Professor Gao Jie from the Rheumatology and Immunology Department of the hospital has successfully developed a universal CD19CAR-NK cell drug for the first time in the world, providing a new treatment option for autoimmune diseases such as systemic lupus erythematosus that currently lack effective treatment methods. The relevant results were recently published in the top international medical journal, The Lancet. It is reported that there has been some progress in the treatment of systemic lupus erythematosus in recent years, especially with the application of biologics that have improved the overall response rate of patients. However, more than half of the patients still do not respond or experience repeated relapses. How to reconstruct the immune homeostasis of patients through the application of new treatment methods is an urgent scientific challenge in the field of autoimmune diseases worldwide. Zhao Dongbao introduced that the root cause of systemic lupus erythematosus is the production of autoantibodies by B cells in the patient's immune system. Therefore, targeted clearance of B cells has become a key step in treatment. The team innovatively utilized natural killer cells from healthy individuals and successfully developed a drug called KN5501 through genetic engineering based on a widely expressed leukocyte differentiation antigen CD19 in B cells. Research has shown that the vast majority of patients with systemic lupus erythematosus can achieve deep B cell clearance with initial B cell reconstruction, ultimately leading to persistent immune tolerance and disease remission. Research has shown that this therapy completely avoids toxic side effects such as femoral head necrosis that may be caused by traditional treatment, significantly improves patients' quality of life, and can restore work ability. Compared with autologous CAR-T technology, it demonstrates better safety and clinical accessibility. (New Society)